| |
property for sale in balchik varna brovets bansko bulgaria
News and Information Article
MADISON, Wis., Sept. 6 // -- Caden Biosciences, Inc., a life
sciences tools and services company developing assays for the
high-throughput screening of allosteric modulators of G-Protein Coupled
Receptors (GPCRs), has closed on a Series A Preferred Stock financing led
by Baird Venture Partners (BVP), the U.S.-based venture capital affiliate
of investment firm Robert W. Baird & Co. (Baird). BVP was joined in the
financing by new investors including Venture Investors, The State of
Wisconsin Investment Board, and IllinoisVENTURES, LLC., as well as existing
investor Vanderbilt University. Caden will leverage its proprietary
platform technology to develop best-in- class assays that will enable its
customers in the pharmaceutical and biotech industries to identify novel
therapeutics for both well characterized and, until now, intractable GPCR
targets.
Pete Shagory of BVP and Paul Weiss, PhD, representing the interests of
Venture Investors, will join the companys Board of Directors. The company
also announced its plan to relocate its headquarters to Madison, Wis.
"Caden Biosciences technology portfolio is exciting because it
provides a universally applicable assay platform for all GPCR signaling
pathways. It is also the most rational and definitive approach to finding
allosteric modulators of GPCRs," said Bill Checovich, PhD, the companys
new President & COO. Dr. Checovich brings to Caden Biosciences 13 years of
executive level operations, product development, and commercialization
experience in the life sciences tools and services industry, having most
recently led operations for Invitrogens Discovery Solutions business unit
in Madison, Wis. "Our unique ability to develop and commercialize discovery
assays for each GPCR/G-protein interaction allows us to support the
pharmaceutical industrys ongoing commitment to GPCRs."
Previously known as Cue Biotech, Inc., the companys name change and
relocation reflect its commitment to exclusively focus on its core business
of developing assays and providing solutions to its pharmaceutical industry
partners.
"We are extremely pleased to lead this investment in Caden Biosciences,
which we believe has a robust and differentiated screening technology that
can interrogate specific GPCR targets in a way not previously possible,
leading to novel, therapeutically relevant drug candidates," said Pete
Shagory, a Partner at BVP. "The pharmaceutical community has long been
searching for new methodologies to improve their therapeutic pipelines,
especially for GPCRs, and Caden Biosciences technology addresses the
growing industry interest in allosteric modulators. We also feel Madison is
an ideal location for the company due to the regions concentration of
scientific and operational talent, and the demonstrated success of tools
and reagents companies in this community."
About Caden Biosciences
Caden Biosciences technology focuses on G-protein coupled receptors
(GPCRs), the most attractive and well-validated class of protein drug
targets. GPCRs have been implicated in every major disease category and
sales of existing therapeutics targeting these receptors exceed $40 billion
annually. Since its inception in 2000, Caden Biosciences has established
collaborations with leading pharmaceutical and biotech companies around its
unique technology that allows companies to identify modulators of GPCRs.
Cadens assays open up new chemical space for receptors already
commercialized and addresses GPCRs previously thought intractable, while
having the potential to develop drugs with fewer side effects and higher
efficacy. For more information, please visit
http://www.cadenbiosciences.com .
About Baird Venture Partners
Baird Venture Partners, the U.S.-based venture capital fund of Baird
Private Equity, makes investments in early- to growth-stage companies in
the Business Services and Healthcare/Life Sciences sectors. Baird Venture
Partners leverages its in-depth sector knowledge, experienced investment
team and network of relationships to serve as a value-added partner for its
portfolio companies. For more information, please visit
http://www.bairdventurepartners.com .
Baird Private Equity, the global private equity group affiliated with
Robert W. Baird & Co. (Baird), makes venture capital, change-in-control and
growth equity investments through Baird Venture Partners and Baird Capital
Partners in the United States and through Baird Capital Partners Europe
(UK) and Granville Baird Capital Partners (Germany) in Europe. With more
than 40 investment professionals in the United States and Europe and 20
operating professionals in China, Baird Private Equity has raised and
managed $1.7 billion in capital. Baird Private Equitys operating team in
China, located in three offices, focuses on facilitating and executing Asia
sourcing, manufacturing and distribution opportunities for portfolio
companies. The groups investments are supported by Bairds full range of
financial advice, operating expertise and industry research, providing a
unique full-service approach to the entire private equity investment
process.
About Venture Investors
Venture Investors is a provider of seed and early stage venture capital
with a principal focus on companies formed to commercialize technologies
developed at leading research universities in the Midwest. Formed in 1982
and based in the MGE Innovation Center in University Research Park for the
University of Wisconsin-Madison, Venture Investors manages over $150
million. Venture Investors provides its portfolio companies with access to
a broad range of expertise through its team of partners that have a
combination of venture capital, entrepreneurial, and operating experience
at stages of development ranging from company formation through initial
public offering. For more information, please visit
http://www.ventureinvestors.com .
About IllinoisVENTURES
IllinoisVENTURES is a seed and early-stage technology investment firm
focused on research-derived companies in information technologies, physical
sciences and life sciences, with a particular emphasis on those deriving
from research conducted at the University of Illinois and other regional
research institutions. IllinoisVENTURES works with inventors &
entrepreneurs to mold concepts, vision, intellectual property, sweat and
passion into breakthrough, high-growth companies, and was recently named by
Entrepreneur magazine to its 2005 list of the top 100 venture capital firms
nationally for entrepreneurs. For more information, please visit
http://www.illinoisventures.com .
| |
|
|
 |
property for sale in balchik varna brovets bansko bulgaria |
|
|
|
|
|
|
|
|
|
Locations
